iShares Nasdaq Biotechnology ETF (IBB) Shares Sold by Winfield Associates Inc.

Winfield Associates Inc. decreased its holdings in iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 2.0% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 29,240 shares of the financial services provider’s stock after selling 602 shares during the period. iShares Nasdaq Biotechnology ETF comprises approximately 1.8% of Winfield Associates Inc.’s investment portfolio, making the stock its 14th biggest holding. Winfield Associates Inc.’s holdings in iShares Nasdaq Biotechnology ETF were worth $3,566,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the business. Schroder Investment Management Group acquired a new position in shares of iShares Nasdaq Biotechnology ETF in the second quarter valued at approximately $105,000. Benjamin F. Edwards & Company Inc. grew its position in shares of iShares Nasdaq Biotechnology ETF by 636.4% in the third quarter. Benjamin F. Edwards & Company Inc. now owns 891 shares of the financial services provider’s stock valued at $109,000 after purchasing an additional 770 shares during the last quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new position in shares of iShares Nasdaq Biotechnology ETF in the second quarter valued at approximately $134,000. KHP Capital LLC grew its position in shares of iShares Nasdaq Biotechnology ETF by 61.1% in the second quarter. KHP Capital LLC now owns 1,450 shares of the financial services provider’s stock valued at $159,000 after purchasing an additional 550 shares during the last quarter. Finally, Private Wealth Advisors Inc. acquired a new position in shares of iShares Nasdaq Biotechnology ETF in the second quarter valued at approximately $201,000. Hedge funds and other institutional investors own 63.62% of the company’s stock.

iShares Nasdaq Biotechnology ETF stock opened at $110.63 on Thursday. iShares Nasdaq Biotechnology ETF has a 12 month low of $100.22 and a 12 month high of $122.97.

COPYRIGHT VIOLATION WARNING: “iShares Nasdaq Biotechnology ETF (IBB) Shares Sold by Winfield Associates Inc.” was originally posted by WKRB News and is the sole property of of WKRB News. If you are accessing this article on another site, it was copied illegally and reposted in violation of U.S. & international copyright laws. The correct version of this article can be accessed at https://www.wkrb13.com/2018/11/09/ishares-nasdaq-biotechnology-etf-ibb-shares-sold-by-winfield-associates-inc.html.

iShares Nasdaq Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Featured Article: Yield Curve

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB).

Institutional Ownership by Quarter for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply